Cardiol Therapeutics (NASDAQ: CRDL) sets June 24 virtual AGM webcast

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. is informing investors that its 2026 virtual Annual General Meeting of Shareholders will be webcast on June 24, 2026, at 4:30 p.m. EDT via an online portal, with participation and voting details available through the company’s investor relations website.

The company highlights its focus on anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule candidate CardiolRx™, which targets inflammasome pathway activation. CardiolRx™ is being evaluated in recurrent pericarditis through the MAVERIC Program, including a completed Phase II pilot study and an ongoing pivotal Phase III trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.

Key Figures

AGM date and time: June 24, 2026, 4:30 p.m. EDT Heart failure healthcare costs: US$30 billion per year Orphan Drug Designation: Granted for pericarditis +4 more

7 metrics

AGM date and time June 24, 2026, 4:30 p.m. EDT Timing of virtual Annual General Meeting webcast

Heart failure healthcare costs US$30 billion per year Estimated annual heart failure-related healthcare costs in the United States

Orphan Drug Designation Granted for pericarditis U.S. FDA designation for CardiolRx™ in pericarditis, including recurrent pericarditis

Phase II MAvERIC-Pilot Phase II Completed pilot study of CardiolRx™ in recurrent pericarditis

MAVERIC trial Phase III Ongoing pivotal trial of CardiolRx™ in recurrent pericarditis

ARCHER study phase Phase II Completed study of CardiolRx™ in acute myocarditis

Sudden cardiac death age reference Under 35 years Acute myocarditis cited as a leading cause of sudden cardiac death in individuals under 35

Key Terms

Annual General Meeting of Shareholders, inflammasome pathway activation, Orphan Drug Designation, recurrent pericarditis, +2 more

6 terms

Annual General Meeting of Shareholders financial

"the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast"

inflammasome pathway activation medical

"CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role"

Orphan Drug Designation regulatory

"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

recurrent pericarditis medical

"The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis"

Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.

acute myocarditis medical

"The ARCHER Program also studied CardiolRx™ in acute myocarditis--an important cause of acute and fulminant heart failure"

Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.

forward-looking information regulatory

"This news release contains "forward-looking information" within the meaning of applicable securities laws"

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/23/2026 - 07:43 AM Accepted by SEC EDGAR 06/23/2026 - 07:43 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated June 23, 2026 - Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: June 23, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

EXHIBIT 99.1

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

TORONTO, June 23, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at 4:30 p.m. EDT.

Cardiol Therapeutics' 2026 AGM

When: June 24, 2026, at 4:30 p.m. EDT
Where: Virtual meeting only via live webcast online at: meetings.lumiconnect.com/400-405-294-535

Additional information about the AGM, including details on how to participate and vote, is available on the Company's website at cardiolrx.com/investors/events-presentations/.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx^™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx^™ in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx^™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx^™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; and the Company's ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-pm-edt-302807049.html

SOURCE Cardiol Therapeutics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2026/23/c2412.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 23-JUN-26

FAQ

When is Cardiol Therapeutics (CRDL) holding its 2026 virtual AGM webcast?

Cardiol Therapeutics will webcast its 2026 virtual Annual General Meeting of Shareholders on June 24, 2026, at 4:30 p.m. EDT. Shareholders can attend online via the specified webcast link and access participation and voting instructions on the company’s investor relations website.

How can Cardiol Therapeutics (CRDL) shareholders access the virtual AGM webcast?

Shareholders can access the AGM through a live webcast hosted at meetings.lumiconnect.com/400-405-294-535. Additional details on how to log in, participate, and vote are available on Cardiol’s website under the investors events and presentations section, ensuring shareholders can join remotely.

What is Cardiol Therapeutics’ lead drug candidate CardiolRx™ targeting?

CardiolRx™ is Cardiol Therapeutics’ lead small-molecule drug candidate targeting inflammasome pathway activation. This pathway is linked to inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure, which the company aims to treat through its ongoing clinical development programs.

What clinical trials are evaluating CardiolRx™ at Cardiol Therapeutics (CRDL)?

CardiolRx™ is being evaluated in the MAVERIC Program for recurrent pericarditis, including a completed Phase II pilot and an ongoing pivotal Phase III trial. It was also studied in the Phase II ARCHER trial in acute myocarditis, assessing safety, tolerability, and efficacy in that patient population.

Does Cardiol Therapeutics’ CardiolRx™ have any FDA designations?

The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. This designation is intended for therapies targeting rare conditions and may provide certain regulatory and economic incentives to support ongoing development work.

What is CRD-38 in Cardiol Therapeutics’ development pipeline?

CRD-38 is a novel, subcutaneously administered drug formulation Cardiol is developing for inflammatory heart disease, including heart failure. Heart failure is described as a leading cause of death and hospitalization in developed countries, with related U.S. healthcare costs exceeding US$30 billion annually.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED JUNE 23, 2026 8.6 KB